Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

respiratory insufficiency/fever

リンクがクリップボードに保存されます
ページ 1 から 89 結果

N-terminal Pro B-type Natriuretic Peptide and Vitamin D Levels as Prognostic Markers in COVID-19 Pneumonia

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern. An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has

Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Ta1 is a naturally occurring peptide that has been evaluated for its immunomodulatory activities and related therapeutic potential in several conditions and diseases, including infectious disease and cancer. ZADAXIN® brand Ta1 is a synthetic version currently approved for use in 37 countries; in

Suloexide in the Treatment of Early Stages of COVID-19

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Objective: To use sulodexide in patients that have early onset of COVID-19 symptoms to mitigate the progression of the disease process that can allow them to recover at home, and limit the need for hospital care and the more severe manifestation which includes fulminant respiratory failure, acute

Therapeutic Plasma Exchange (TPE) for Covid-19 Cytokine Release Storm (CRS)

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
PROTOCOL SUMMARY: Long title: Proposed use of TPE (therapeutic plasma exchange), to Limit Coronavirus Associated Complications: An Open label, Phase 2 Study Clinical Phase: Two arms, Phase 2 Open Label Conducted by: Department of Pulmonology and Critical Care; Pak Emirates Military Hospital. Sample

Role of Co-trimoxazole in Severe COVID-19 Patients

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Coronavirus disease (COVID-19) caused by SARS-COV2, represents a highly transmissible and potentially fatal disease that is of great global public health concern at this moment. The pandemic situation in Bangladesh is also evolving rapidly with positive cases and deaths increasing each day.

Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
The novel coronavirus (SARS-CoV-2), is a single-stranded RNA coronavirus. The virus was first isolated from patients presented with pneumonia in Wuhan in December 2019.Sequences of the Wuhan betacoronavirus show similarities to betacoronaviruses found in bats, sharing a common ancestor with the 2003

Hesperidin and Diosmin for Treatment of COVID-19

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Research Background and Rationale At the end of December 2019, pneumonia of unknown origin was detected in the hospitals of Wuhan city, China, and reported to the WHO country office for the first time [1-3]. After a few days, the Chinese government has confirmed the human-to-human transmission of
Coronavirus-induced disease 2019 (COVID-19) caused by SARS-CoV-2 infection is a highly contagious disease with a high and unpredictable morbidity and mortality, for which there is currently no specific treatment. Progression from a mild fatigue, fever and cough, to severe respiratory failure

Clinical Study for the Treatment With Interferon-ß-1a (IFNß-1a) of COVID-19 Patients

登録ユーザーのみが記事を翻訳できます
ログインサインアップ

Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
In December, 2019, an outbreak of pneumonia with unknown cause occurred in Wuhan city, the capital of Hubei province in China. On January 7th, the scientists succeeded to isolate a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). WHO nominated it as coronavirus

BNP, Serum Troponin and D-dimer as Risk Factors in Patients With COVID-19

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Coronavirus disease-2019 (COVID-19), a contagious novel coronavirus now called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; formerly called 2019-nCoV). Cardiac injury is a common condition among the hospitalized patients with COVID-19. It t was recently reported that 19.7% patients

Reliability of a Pocket Sized Ultrasound Scanner in the Evaluation Covid-19 Pneumonia

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China in December 2019 and quickly spread all over the globe. The clinical features are fever, dyspnoea, dry cough, fatigue and diarrhoea (1). Pharyngodynia, nasal

Rehabilitation Needs After COVID-19 Hospital Treatment

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
The onset of Coronavirus Disease 2019 (COVID-19) in the first months of 2020 had a huge impact on Italian population and Healthcare System, with more than 150.000 total confirmed cases. SARS-CoV-2 is a highly contagious new virus, causing an influenza like illness and respiratory tract infection

Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Patients with the most severe type of sepsis, those with septic shock have a mortality rate between 30% to 45% due to multiple organ failure. The poor outcome of shocked patients, and especially those with sepsis, may by related to microvascular endothelial dysfunction. Coronavirus disease 2019

Core Warming of COVID-19 Patients

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Participants will be randomized in a 1:1 fashion to core warming with the study device (ensoETM) or to standard of care (standard temperature management and treatment). The device will be used as indicated (for warming). Patient temperature measurement will be collected for both the core warming and
Facebookページに参加する

科学に裏打ちされた最も完全な薬草データベース

  • 55の言語で動作します
  • 科学に裏打ちされたハーブ療法
  • 画像によるハーブの認識
  • インタラクティブGPSマップ-場所にハーブをタグ付け(近日公開)
  • 検索に関連する科学出版物を読む
  • それらの効果によって薬草を検索する
  • あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください

症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています

Google Play badgeApp Store badge